154 related articles for article (PubMed ID: 32111493)
41. Changes in protein profiles of multiple myeloma cells in response to bortezomib.
Turan T; Sanlı-Mohamed G; Baran Y
Leuk Lymphoma; 2013 May; 54(5):1061-8. PubMed ID: 23025401
[TBL] [Abstract][Full Text] [Related]
42. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
[TBL] [Abstract][Full Text] [Related]
43. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling.
Xu B; Li J; Xu D; Ran Q
Ir J Med Sci; 2023 Apr; 192(2):561-567. PubMed ID: 35508865
[TBL] [Abstract][Full Text] [Related]
44. [Rosiglitazone and all-trans retinoic acid inhibit human myeloma cell proliferation via apoptosis signaling pathway modulation].
Huang HW; Wu DP; Chen GH; Chang HR; Chow HC; Leung AY; Liang R
Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):242-6. PubMed ID: 19731824
[TBL] [Abstract][Full Text] [Related]
45. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
[TBL] [Abstract][Full Text] [Related]
46. [Atractylenolide I Can Induce Apoptosis of U266 Cells and Enhance Bortezomib Effect].
Mai ZX; Yu TQ; Fan TT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):177-184. PubMed ID: 32027273
[TBL] [Abstract][Full Text] [Related]
47. Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis.
Zhang Y; Zhu X; Hou K; Zhao J; Han Z; Zhang X
Oncol Rep; 2015 May; 33(5):2277-84. PubMed ID: 25812695
[TBL] [Abstract][Full Text] [Related]
48. [Establishment of BOR-Resistant U266 Cell Line and the Detection of Its Biological Activities].
Liu HL; Que WZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1722-1726. PubMed ID: 29262905
[TBL] [Abstract][Full Text] [Related]
49. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2.
Tian F; Zhan Y; Zhu W; Li J; Tang M; Chen X; Jiang J
Int J Mol Med; 2019 Feb; 43(2):1058-1066. PubMed ID: 30535471
[TBL] [Abstract][Full Text] [Related]
51. [Apoptosis in Jurkat cells induced by bortezomib combined with adriamycin].
Chen JF; Jin J
Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):890-3. PubMed ID: 20193325
[TBL] [Abstract][Full Text] [Related]
52. Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma.
Yokokura S; Yurimoto S; Matsuoka A; Imataki O; Dobashi H; Bandoh S; Matsunaga T
BMC Cancer; 2014 Nov; 14():882. PubMed ID: 25424011
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma.
Ma J; Wang S; Zhao M; Deng XS; Lee CK; Yu XD; Liu B
BMC Cancer; 2011 Jun; 11():255. PubMed ID: 21679466
[TBL] [Abstract][Full Text] [Related]
54. Establishment of stable multiple myeloma cell line with overexpressed PDCD5 and its proapoptosis mechanism.
Feng W; Fu Y; Zhang Y; Lv B; Li X; Zhang F; Gui R; Liu J
Int J Clin Exp Pathol; 2015; 8(9):10635-43. PubMed ID: 26617773
[TBL] [Abstract][Full Text] [Related]
55. [Effect of 20 (S)-ginsenoside Rg3 on the proliferation inhibition and secretion of vascular endothelial growth factor of multiple myeloma cell line U266].
Song Y; Hou J; Kang L; Gao S
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):519-23. PubMed ID: 24985176
[TBL] [Abstract][Full Text] [Related]
56. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
[TBL] [Abstract][Full Text] [Related]
57. Bortezomib Targets Sp Transcription Factors in Cancer Cells.
Karki K; Harishchandra S; Safe S
Mol Pharmacol; 2018 Oct; 94(4):1187-1196. PubMed ID: 30115673
[TBL] [Abstract][Full Text] [Related]
58. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.
Fandy TE; Shankar S; Ross DD; Sausville E; Srivastava RK
Neoplasia; 2005 Jul; 7(7):646-57. PubMed ID: 16026644
[TBL] [Abstract][Full Text] [Related]
59. [2-methoxyestradiol disrupts aggresomes induction by bortezomib and potentiates apoptosis in multiple myeloma cells.].
Ma YL; Jiang H; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2009 Nov; 30(11):754-7. PubMed ID: 20137311
[TBL] [Abstract][Full Text] [Related]
60. [MS-275, a histone deacetylase inhibitor, induces apoptosis and alters survivin gene expression in human myeloma cell line U266].
Ma J; Zhao M; Yu XD; Wang ZH
Ai Zheng; 2009 May; 28(5):466-71. PubMed ID: 19624872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
